UNASSIGNED:评估在预测结节病的晚期疾病阶段以及区分活动性和稳定性疾病中,在初始诊断时确定的中性粒细胞-淋巴细胞比率(NLR)的实用性。
UNASSIGNED:共465例经活检证实的结节病患者(年龄:47岁,70.5%的女性)被纳入这项回顾性横断面研究。患者人口统计数据,结节病阶段,临床状态(稳定和活跃),抗炎治疗,全血细胞计数,和炎症标志物,包括红细胞沉降率(ESR),C反应蛋白(CRP),记录中性粒细胞/淋巴细胞比值(NLR)和血小板/平均血小板体积(MPV)比值.根据结节病的分期和临床状态对患者进行分组,比较NLR值,同时绘制受试者工作特征(ROC)曲线,以确定NLR在疾病活动鉴定中的作用,并通过ROC分析计算曲线下面积(AUC)和临界值。
未经评估:总的来说,活跃,36例(7.8%)和427例(92.2%)患者病情稳定,分别。与疾病稳定患者相比,活动性疾病患者的NLR中位数明显更高(3.31(2.34-4.31)2.29(1.67-3.23),p=0.005)。晚期结节病阶段与阶段0、I、II,III和IV,分别(p=0.001)。ROC分析显示NLR截止值≥2.39(AUC(95%CI):0.70(0.62-0.79),p<0.001)以72.0%的灵敏度和52.0%的特异性区分活跃和稳定的临床。活跃患者的百分比明显高于疾病稳定的NLR值≥2.39(74.0vs.47.0%,p=0.002)。
UNASSIGNED:我们的研究结果表明,入院时NLR值在预测疾病晚期的风险以及区分结节病的活动性和稳定性疾病方面具有潜在的实用性。通过简单的测量,随时可用,和低成本测试,NLR似乎是监测疾病活动和进展的有价值的标志物。
UNASSIGNED: To evaluate the utility of neutrophil-lymphocyte ratio (NLR) determined at initial diagnosis in predicting advanced disease stage and discriminating between active and stable disease in sarcoidosis.
UNASSIGNED: A total of 465 patients with biopsy-proven sarcoidosis (age: 47 years, 70.5% females) were included in this retrospective cross-sectional
study. Data on patient demographics, sarcoidosis stage, clinical status (stable and active), anti-inflammatory treatments, complete blood count, and inflammatory markers including erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), neutrophil-to-lymphocyte ratio (NLR) and platelet/mean platelet volume (MPV) ratio were recorded. NLR values were compared by subgrouping the patients according to the stage of sarcoidosis and clinical status, while the receiver operating characteristics (ROC) curve was plotted to determine the role of NLR in the identification of disease activity with the calculation of area under the curve (AUC) and cutoff value via ROC analysis.
UNASSIGNED: Overall, active, and stable disease was evident in 36 (7.8%) and 427 (92.2%) patients, respectively. Median NLR values were significantly higher in patients with active disease compared with stable disease (3.31 (2.34-4.31) vs. 2.29 (1.67-3.23), p = 0.005). Advanced sarcoidosis stage was associated with significantly higher NLR values at stages 0, I, II, III and IV, respectively (p = 0.001). ROC analysis revealed an NLR cutoff value of ≥2.39 (AUC (95% CI): 0.70 (0.62-0.79), p < 0.001) to discriminate between active and stable clinic with a sensitivity of 72.0% and specificity of 52.0%. The significantly higher percentage of patients with active vs. stable disease had NLR values ≥2.39 (74.0 vs. 47.0%, p = 0.002).
UNASSIGNED: Our findings indicate the potential utility of on-admission NLR values to predict the risk of advanced disease stage and to discriminate between active and stable disease in sarcoidosis. Measured via a simple, readily available, and low-cost test, NLR seems to be a valuable marker for monitoring disease activity and progression.